Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | CRHBP | P24387 | 1/20 | 0.59 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12608918 | 0.90 | ADORA1 (0.82) | ADORA1MEN1KMT2AMAPTLMNA | |
| SCHEMBL16007300 | 0.87 | ADORA1 (0.80) | ADORA1MEN1KMT2AMAPTLMNA | |
| SCHEMBL5712840 | 0.86 | ADORA1 (0.76) | ADORA1MEN1KMT2AMAPTLMNA | |
| Tinoridine SCHEMBL24761 | 0.85 | ADORA1 (1.00) | ADORA1MEN1KMT2AMAPTLMNA | |
| SCHEMBL5676520 | 0.85 | ADORA1 (0.74) | ADORA1MEN1KMT2AMAPTLMNA | |
| SCHEMBL138362 | 0.85 | ADORA1 (0.74) | ADORA1MEN1KMT2AMAPTLMNA | |
| SCHEMBL5676765 | 0.84 | ADORA1 (0.72) | ADORA1MEN1KMT2AMAPTLMNA | |
| SCHEMBL5676492 | 0.84 | ADORA1 (0.72) | ADORA1MEN1KMT2AMAPTLMNA | |
| SCHEMBL5676456 | 0.84 | ADORA1 (0.72) | ADORA1MEN1KMT2AMAPTLMNA | |
| Tinoridine SCHEMBL217049 | 0.84 | ADORA1 (0.98) | ADORA1MEN1KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140057959-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | UNIVERSIDADE ESTADUAL PAULISTA JULIO DE MESQUITA FILHO - UNESP (BR) | 2014-02-27 | — | — | US | claimed |
| US-8569335-B2 | Compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these | EMS S.A. (BR) | 2013-10-29 | — | — | US | claimed |
| US-20110118303-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | EMS S.A. (BR) | 2011-05-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057959-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | TPMT, UTS2R, NSUN3 | ADORA1 565/4885MEN1 4588/4885KMT2A 1891/4885 |
| US-20110118303-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | TPMT, UTS2R, NSUN3 | ADORA1 565/4885MEN1 4588/4885KMT2A 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.